Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Revolution Medicines
ISIN US76155X1000
|WKN A2PYWG
Market cap (in EUR)
17,795 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 17,795 m |
| EPS, EUR | -4.69 |
| P/B ratio | 12.8 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | - |
| Net income, EUR | -555 m |
| Profit margin | - |
What ETF is Revolution Medicines in?
There are 29 ETFs which contain Revolution Medicines. All of these ETFs are listed in the table below. The ETF with the largest weighting of Revolution Medicines is the Harbor Health Care UCITS ETF Accumulating.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.